Viridian Therapeutics, Inc. – NASDAQ:VRDN

Add to watchlist

$17.81

-1.64

-8.43%

Market closed

Open in about 6 hours

+40.03%

month

+40.03%

quarter

-13.56%

year

Market Cap	1.50B
Enterprise value	652.21M

P/E	-6.18
EV/Sales	462.23
EV/EBITDA	-5.04
Price/Sales	569.20
Price/Book	2.03
PEG ratio	-0.15
EPS	-4.5

Revenue	288K
EBITDA	-227.68M
Income	-218.12M
Revenue Q/Q	-26.53%
Revenue Y/Y	-82.58%

Profit margin	-9204.39%
Oper. margin	-9518.36%
Gross margin	0%
EBIT margin	-9518.36%
EBITDA margin	-79055.56%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Viridian Therapeutics Stock Forecast

M Q Y

Last Year

$38

Potential upside: 113.36%

Analysts Price target
Financials & Ratios estimates

Viridian Therapeutics, Inc. (NASDAQ:VRDN): Profit margin
Jun 2023	72K	-55.06M	-76476.39%
Sep 2023	72K	-47.66M	-66194.44%
Dec 2023	72K	-66.86M	-92861.11%
Mar 2024	72K	-48.54M	-67419.44%

Viridian Therapeutics, Inc. (NASDAQ:VRDN): Debt to assets
Jun 2023	351467000	35.61M	10.13%
Sep 2023	328757000	45.18M	13.74%
Dec 2023	490424000	48.40M	9.87%
Mar 2024	630381000	47.85M	7.59%

Viridian Therapeutics, Inc. (NASDAQ:VRDN): Cash Flow
Jun 2023	-45.21M	40.71M	3.06M
Sep 2023	-38.98M	48.04M	15.45M
Dec 2023	-38M	-169.71M	198.94M
Mar 2024	-45.22M	-143.04M	177.08M

Viridian Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Viridian Therapeutics
Employees

Viridian Therapeutics, Inc. (NASDAQ:VRDN): Employee count
Aug 2023	86
Sep 2023	86
Oct 2023	86
Nov 2023	86
Dec 2023	86
Jan 2024	86
Feb 2024	86
Mar 2024	94
Apr 2024	94
May 2024	94
Jun 2024	94
Jul 2024	94

Viridian Therapeutics
Hedge Funds Holdings Q1 2023

33.07% -66.93%

of VRDN is owned by hedge funds

66 -57

hedge funds hold VRDN stock

10.61M -30.68M

shares is hold by hedge funds

VRDN hedge funds holdings changes

Viridian Therapeutics
Insider Trading

Viridian Therapeutics, Inc. (NASDAQ:VRDN): Insider trades (number of shares)
Period	Buy	Sel
Feb 2023	0	100000
Mar 2023	5500	29971
Apr 2023	4000	0
Jun 2023	0	9796
Jan 2024	476190	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	22 Jan 2024	FAIRMOUNT FUNDS MANAGEMENT LLC director, 10 percent owner,.. director, 10 percent owner, oth..	Common Stock	476,190	$21	$9,999,990
Option	16 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	27	$23.03	$622
Sale	16 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	27	$28.35	$765
Option	16 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right to Buy)	28	$23.03	$645
Option	15 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	2,269	$23.03	$52,255
Sale	15 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	2,269	$28.02	$63,577
Option	15 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right to Buy)	2,269	$23.03	$52,255
Option	6 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	5,126	$18.51	$94,882
Sale	6 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	5,126	$25.02	$128,253
Option	6 Jun 2023	MEISNER LARA officer: Chief Legal Officer officer: Chief Legal Officer	Stock Option (Right to Buy)	5,126	$18.51	$94,882

VRDN insider trading transactions

Viridian Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q1 2023 13 May 2023	Q1 2023 Earnings Call Transcript
Q3 2022 14 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 15 Aug 2022	Q2 2022 Earnings Call Transcript

VRDN earnings call transcripts

Viridian Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. William Stuart Marshall Ph.D. (1964) Co-Founder & Senior Technical Advisor	61		$1,600,000

Viridian Therapeutics
Latest News

Thursday, 19 December 2024
10:34	Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)	seekingalpha.com
Wednesday, 18 December 2024
10:56	Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation	seekingalpha.com
Tuesday, 17 December 2024
12:41	Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)	seekingalpha.com
Monday, 16 December 2024
09:28	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease	investors.com
07:10	Viridian Therapeutics' eye disorder drug meets late-stage study goal	reuters.com
07:00	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease	businesswire.com
Friday, 13 December 2024
18:00	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024	businesswire.com
Wednesday, 4 December 2024
16:01	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 12 November 2024
09:26	Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Wednesday, 23 October 2024
16:02	Viridian Therapeutics' Superior Prospects Make It A Buy	seekingalpha.com
Thursday, 19 September 2024
12:54	3 Small Biotech Stocks With The 'Big Mo' Right Now	seekingalpha.com
Wednesday, 11 September 2024
23:25	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock	businesswire.com
12:30	VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints	zacks.com
Tuesday, 10 September 2024
17:09	Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way	seekingalpha.com
10:58	Biotech Stock Scores Big Win, Squeezes Shorts	schaeffersresearch.com
07:18	Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study	reuters.com
Thursday, 8 August 2024
10:25	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
Monday, 29 July 2024
15:32	3 Biotech Names With Potential Catalysts By Year End	seekingalpha.com
Wednesday, 17 July 2024
08:05	Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?	zacks.com
Monday, 8 July 2024
10:38	3 Small-Cap Stocks With Explosive 2X Growth Potential	investorplace.com
Wednesday, 12 June 2024
10:29	Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year	seekingalpha.com
10:16	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug	zacks.com
Tuesday, 11 June 2024
06:00	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease	businesswire.com
Thursday, 6 June 2024
16:01	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 31 May 2024
08:00	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences	businesswire.com
Friday, 10 May 2024
08:00	Viridian Therapeutics to Participate in Upcoming May Investor Conferences	businesswire.com
Wednesday, 8 May 2024
14:27	Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript	seekingalpha.com
09:25	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 19 March 2024
18:51	Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20	InvestorPlace
Wednesday, 28 February 2024
10:56	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 9 Jun 2025

Viridian Therapeutics: The Song Remains The Same
Seeking Alpha 19 Dec 2024

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Seeking Alpha 18 Dec 2024

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Seeking Alpha 17 Dec 2024

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Seeking Alpha 12 Jun 2024

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Seeking Alpha 29 Dec 2023

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023
Seeking Alpha 12 Dec 2023

Viridian: Market May Be Wrong In Its Disapproval
Seeking Alpha 13 Jul 2023

Viridian: Despite Drop, Advancement Towards Phase 3 Continues
Seeking Alpha 11 Apr 2023

Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price
Seeking Alpha 25 Jan 2023

Why Viridian Therapeutics Is One Of My 2023 Top Picks

Frequently Asked Questions (FAQ)

What's the price of Viridian Therapeutics stock today?

One share of Viridian Therapeutics stock can currently be purchased for approximately $17.81.
When is Viridian Therapeutics's next earnings date?

Unfortunately, Viridian Therapeutics's (VRDN) next earnings date is currently unknown.
Does Viridian Therapeutics pay dividends?

No, Viridian Therapeutics does not pay dividends.
How much money does Viridian Therapeutics make?

Viridian Therapeutics has a market capitalization of 1.50B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 82.28% to 314K US dollars.
What is Viridian Therapeutics's stock symbol?

Viridian Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VRDN".
What is Viridian Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Viridian Therapeutics?

Shares of Viridian Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Viridian Therapeutics's key executives?
Viridian Therapeutics's management team includes the following people:
- Dr. William Stuart Marshall Ph.D. Co-Founder & Senior Technical Advisor(age: 61, pay: $1,600,000)
Is Viridian Therapeutics founder-led company?

Yes, Viridian Therapeutics is a company led by its founder Dr. William Stuart Marshall Ph.D..
How many employees does Viridian Therapeutics have?

As Jul 2024, Viridian Therapeutics employs 94 workers.
When Viridian Therapeutics went public?

Viridian Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 18 Jun 2014.
What is Viridian Therapeutics's official website?

The official website for Viridian Therapeutics is viridiantherapeutics.com.
Where are Viridian Therapeutics's headquarters?

Viridian Therapeutics is headquartered at 221 Crescent Street, Waltham, MA.
How can i contact Viridian Therapeutics?

Viridian Therapeutics's mailing address is 221 Crescent Street, Waltham, MA and company can be reached via phone at +61 72724600.
What is Viridian Therapeutics stock forecast & price target?

Based on 6 Wall Street analysts` predicted price targets for Viridian Therapeutics in the last 12 months, the avarage price target is $38. The average price target represents a 113.36% change from the last price of $17.81.

Viridian Therapeutics, Inc.

viridiantherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

+61 72724600

221 Crescent Street
Waltham, MA 02453

CIK: 0001590750
ISIN: US92790C1045
CUSIP: 92790C104